AcademicLabs

How much does timing matter in drug development? Does being first, second, or fifth into a therapeutic space really change your company’s fortunes? And what can past examples tell us about smarter portfolio decisions today?

Join pharma strategist **Mark Tillotson** as he unpacks:

*   The relationship between order of entry into R\&D programs and long-term company value.
*   Case studies where herding paid off - and where it destroyed value.
*   Practical implications for how pharma and biotech should approach pipeline and portfolio choices.

Mark will share a fresh analysis powered by recent data - made feasible by AcademicLabs.com - to explore how companies can avoid the risks of herd behavior and redirect resources to higher-impact opportunities.

At the end, you’ll also get a quick look at how you can try the platform and the AI yourself with a complimentary two-week trial.


Leading the pack or following the herd?  The consequences of pipeline asset clustering around targets and implications for portfolio decisions

ClinicalTrials.gov is used by everyone in pharma and biotech.

But when you combine it with AI mapping and disease burden data, you can quickly reveal underinvestigated high-burden diseases areas where trial activity lags behind real patient need.

In this 9-minute case study, pharma strategist Mark Tillotson demonstrates how to:

\- Apply smart filters to focus on the most relevant trials (company-run, ≤Phase III, exclude healthy volunteers)

\- Use AI to map thousands of trials to 172 disease codes in 1 minute instead of days

\- Export a clean Excel of 2,400+ trials with mapped disease codes for deeper analysis

\- Merge with IHME burden data to instantly see where gaps = opportunities

The workflow was done in AcademicLabs, which integrates ClinicalTrials.gov (and patents, publications, grants, news - all connected to 360° company, lab and researcher profiles) with advanced filters and built-in AI for science-grounded insights.

Try it yourself: New users get AI free on day 1 so you can apply a similar workflow across trials, patents, publications, and grants.

Featuring: Mark Tillotson (Therapeutic Area, Pipeline/Portfolio & Commercialization Strategy) and Arne Smolders (founder of AcademicLabs).


ClinicalTrials.gov + AI_ How to Spot Underinvestigated High-Burden Diseases (Case Study)

In this deep-dive session, we’ll show how leading Pharma & Biotech External Innovation, BD, CI, R\&D, Investors and Consultants are using **new AcademicLabs AI capabilities to scout entire scientific spaces in minutes, not weeks**.

*This is not a standard, slow-paced walkthrough. We have designed this session as a ****high-velocity masterclass****. I’ve condensed real-time workflows to remove all loading/processing time, allowing us to cover ****entire landscapes of use cases in 10% of the time****. You will see raw value, zero buffering.*

You’ll learn how to:

*   Generate a **decision-ready, ranked report** on your top 50 KOLs, collaborators, startups, strategic partners
*   Evaluate **2,000 researchers/labs or 1,000 companies in 5 minutes** for instant prioritizing
*   Landscape any novel **targets, preclinical assets, biomarkers, endpoints, technologies**... using new AI capabilities
*   Fast-track solutions for your **Open Innovation Challenges**
*   Leverage our new Company Intelligence v2 or scouting

To make it easier for you to run such analyses by yourself, you will receive:

*   **3 days free** access
*   1000 free/extra **AI credits**
*   all **queries used**
*   all **AI prompts used**

If interested, you can request the **Analysis Outputs** via <arne@academiclabs.com> - I am happy to share them with you.

Perfect for teams involved in **External Innovation, Search & Evaluation, (Early) R\&D Intelligence, Competitive Intelligence, TA Strategy, BD, R\&D, Venture Creation, Investments and Consultants**.
